Home   Contact Palatin   Site Map  

Investor/Media Center

Press Releases

 
2006 2007 2008 2009 all
 
 

2007
Displaying releases: 1-15 | 16-24


  Nov-09-2007 Palatin Technologies, Inc. Reports Fiscal Year 2008 First Quarter Results; Teleconference and Webcast to be held on November 9, 2007
  Nov-05-2007 Palatin Technologies to Report Fiscal Year 2008 First Quarter Results; Teleconference and Webcast on November 9, 2007
  Nov-02-2007 Palatin Technologies to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
  Oct-31-2007 Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
  Sep-27-2007 Palatin Technologies, Inc. Reports Positive Data from an At-home Study of Pre- and Postmenopausal Women with Female Sexual Arousal Disorder Treated with Bremelanotide
  Sep-26-2007 Palatin Technologies Announces Reduction of Workforce
  Sep-14-2007 Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007
  Sep-13-2007 Palatin Technologies To Report Fourth Quarter And Fiscal Year End 2007 Financial Results; Conference Call And Webcast On September 18, 2007
  Sep-12-2007 Palatin Technologies Refutes Competitive Technologies Contention Of Material Breach
  Sep-10-2007 Palatin Technologies Announces Reacquisition Of Full Rights To Bremelanotide Program
  Aug-30-2007 King Pharmaceuticals And Palatin Technologies Delay Immediate Plans For Phase 3 Clinical Program With Bremelanotide For Erectile Dysfunction
  Jun-25-2007 King Pharmaceuticals and Palatin Technologies Announce End-of-Phase 2 Meeting with FDA for Bremelanotide
  May-22-2007 Palatin Technologies and King Pharmaceuticals Report Data Showing Improvements in Sexual Relationship and Self-Esteem in Patients with Erectile Dysfunction Treated with Bremelanotide
  May-11-2007 Palatin Technologies To Present At The Acumen BioFin 4th Annual Global Healthcare Conference
  May-09-2007 Palatin Technologies And King Pharmaceuticals Announce Plan To Present Results Of Bremelanotide Phase 2b Studies In Men With Erectile Dysfunction